David Williams
Concepts (535)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Enzyme Inhibitors | 6 | 2023 | 378 | 0.870 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2023 | 16 | 0.650 |
Why?
| Hypophosphatasia | 1 | 2018 | 8 | 0.630 |
Why?
| Genetic Engineering | 1 | 2018 | 24 | 0.620 |
Why?
| Disease Models, Animal | 5 | 2019 | 1419 | 0.610 |
Why?
| Alkaline Phosphatase | 1 | 2018 | 94 | 0.610 |
Why?
| Phenylenediamines | 1 | 2018 | 5 | 0.600 |
Why?
| Cerebrovascular Circulation | 3 | 2016 | 128 | 0.560 |
Why?
| Proto-Oncogene Proteins c-met | 5 | 2010 | 19 | 0.530 |
Why?
| Retroviridae Infections | 2 | 2013 | 2 | 0.530 |
Why?
| Personnel, Hospital | 2 | 2006 | 20 | 0.520 |
Why?
| Tinnitus | 2 | 2017 | 59 | 0.510 |
Why?
| Transcranial Magnetic Stimulation | 2 | 2017 | 69 | 0.500 |
Why?
| Aminopyridines | 3 | 2010 | 15 | 0.500 |
Why?
| Suction | 2 | 2013 | 23 | 0.470 |
Why?
| Female | 49 | 2024 | 26981 | 0.460 |
Why?
| Amines | 2 | 2014 | 39 | 0.450 |
Why?
| Methamphetamine | 5 | 2014 | 195 | 0.450 |
Why?
| Macaca mulatta | 2 | 2013 | 92 | 0.440 |
Why?
| Humans | 62 | 2024 | 50389 | 0.430 |
Why?
| Xenotropic murine leukemia virus-related virus | 1 | 2012 | 1 | 0.420 |
Why?
| Wounds and Injuries | 2 | 2006 | 281 | 0.410 |
Why?
| Antibodies, Monoclonal | 5 | 2014 | 462 | 0.400 |
Why?
| Male | 44 | 2024 | 25718 | 0.400 |
Why?
| Heart Rate | 5 | 2019 | 311 | 0.390 |
Why?
| Rural Health Services | 2 | 2013 | 168 | 0.390 |
Why?
| Structure-Activity Relationship | 11 | 2023 | 394 | 0.390 |
Why?
| Caregivers | 3 | 2019 | 213 | 0.390 |
Why?
| Protein Kinase Inhibitors | 3 | 2010 | 205 | 0.380 |
Why?
| Intermittent Positive-Pressure Ventilation | 1 | 2011 | 19 | 0.360 |
Why?
| Infant, Very Low Birth Weight | 1 | 2011 | 48 | 0.360 |
Why?
| Obesity | 6 | 2024 | 1125 | 0.360 |
Why?
| Cost-Benefit Analysis | 2 | 2015 | 270 | 0.350 |
Why?
| Depressive Disorder | 2 | 2010 | 336 | 0.350 |
Why?
| United States Department of Veterans Affairs | 3 | 2021 | 288 | 0.350 |
Why?
| Animals | 30 | 2021 | 13173 | 0.340 |
Why?
| Antineoplastic Agents | 5 | 2010 | 1178 | 0.340 |
Why?
| Telemedicine | 3 | 2013 | 468 | 0.340 |
Why?
| Intubation, Intratracheal | 1 | 2011 | 120 | 0.330 |
Why?
| Respiration, Artificial | 2 | 2016 | 292 | 0.330 |
Why?
| Breast Feeding | 2 | 2022 | 189 | 0.330 |
Why?
| Maternal Nutritional Physiological Phenomena | 2 | 2020 | 55 | 0.320 |
Why?
| Dietary Supplements | 3 | 2018 | 445 | 0.310 |
Why?
| Time Factors | 10 | 2020 | 2934 | 0.310 |
Why?
| Insulin Resistance | 2 | 2020 | 264 | 0.290 |
Why?
| Blood Pressure | 4 | 2016 | 529 | 0.290 |
Why?
| Gait Disorders, Neurologic | 2 | 2018 | 36 | 0.290 |
Why?
| Leptin | 2 | 2022 | 143 | 0.280 |
Why?
| Dietary Proteins | 2 | 2020 | 243 | 0.280 |
Why?
| Infant, Newborn | 9 | 2021 | 2780 | 0.270 |
Why?
| Brain | 5 | 2021 | 1313 | 0.270 |
Why?
| Parkinson Disease | 2 | 2018 | 145 | 0.260 |
Why?
| Accidents, Occupational | 1 | 2006 | 20 | 0.260 |
Why?
| Infant, Premature | 5 | 2016 | 319 | 0.250 |
Why?
| Adiposity | 2 | 2024 | 133 | 0.240 |
Why?
| Cerebral Hemorrhage | 2 | 2016 | 99 | 0.240 |
Why?
| Occupational Diseases | 1 | 2006 | 82 | 0.240 |
Why?
| Rats, Sprague-Dawley | 13 | 2014 | 1582 | 0.230 |
Why?
| Pregnancy | 11 | 2024 | 2610 | 0.230 |
Why?
| Cross-Over Studies | 7 | 2017 | 224 | 0.220 |
Why?
| Depression | 3 | 2014 | 572 | 0.220 |
Why?
| Infant, Premature, Diseases | 2 | 2016 | 94 | 0.220 |
Why?
| Veterans | 2 | 2021 | 572 | 0.220 |
Why?
| Insulin | 3 | 2022 | 466 | 0.220 |
Why?
| Ethers | 1 | 2023 | 8 | 0.220 |
Why?
| Internship and Residency | 2 | 2019 | 444 | 0.210 |
Why?
| Executive Function | 2 | 2021 | 70 | 0.210 |
Why?
| Pyrroles | 3 | 2008 | 68 | 0.210 |
Why?
| Stress Disorders, Post-Traumatic | 2 | 2019 | 377 | 0.210 |
Why?
| Sertraline | 2 | 2014 | 46 | 0.210 |
Why?
| Adult | 17 | 2019 | 13568 | 0.200 |
Why?
| Students, Medical | 2 | 2017 | 159 | 0.200 |
Why?
| Maternal-Fetal Exchange | 2 | 2020 | 43 | 0.190 |
Why?
| Pedunculopontine Tegmental Nucleus | 2 | 2012 | 24 | 0.190 |
Why?
| Liver Failure, Acute | 1 | 2022 | 56 | 0.190 |
Why?
| Microsomes, Liver | 4 | 2018 | 182 | 0.190 |
Why?
| HeLa Cells | 2 | 2023 | 257 | 0.190 |
Why?
| Energy Metabolism | 2 | 2021 | 284 | 0.190 |
Why?
| Mice | 14 | 2021 | 5688 | 0.190 |
Why?
| End Stage Liver Disease | 1 | 2022 | 48 | 0.190 |
Why?
| Body Composition | 2 | 2020 | 326 | 0.190 |
Why?
| Middle Aged | 12 | 2019 | 12460 | 0.190 |
Why?
| Phencyclidine | 2 | 2011 | 35 | 0.180 |
Why?
| Rats | 13 | 2014 | 3287 | 0.180 |
Why?
| Myocardium | 2 | 2021 | 444 | 0.180 |
Why?
| Olivary Nucleus | 2 | 2011 | 7 | 0.180 |
Why?
| Myoglobin | 1 | 2021 | 25 | 0.180 |
Why?
| Purkinje Cells | 2 | 2011 | 17 | 0.180 |
Why?
| Evoked Potentials | 1 | 2021 | 72 | 0.180 |
Why?
| Cocaine-Related Disorders | 2 | 2014 | 205 | 0.180 |
Why?
| Infant Food | 1 | 2020 | 28 | 0.180 |
Why?
| Growth | 1 | 2020 | 40 | 0.180 |
Why?
| Spumavirus | 1 | 2020 | 1 | 0.180 |
Why?
| Bottle Feeding | 1 | 2020 | 34 | 0.180 |
Why?
| Body Temperature Regulation | 1 | 2020 | 22 | 0.170 |
Why?
| Crystallography, X-Ray | 6 | 2010 | 148 | 0.170 |
Why?
| Blood Glucose | 2 | 2020 | 443 | 0.170 |
Why?
| Acetaminophen | 2 | 2022 | 274 | 0.170 |
Why?
| Neurons | 3 | 2012 | 455 | 0.170 |
Why?
| Brain Concussion | 1 | 2021 | 106 | 0.170 |
Why?
| Concept Formation | 1 | 2019 | 12 | 0.170 |
Why?
| Temperature | 1 | 2020 | 165 | 0.170 |
Why?
| Genome, Viral | 1 | 2020 | 79 | 0.170 |
Why?
| Phenotype | 2 | 2021 | 736 | 0.170 |
Why?
| Energy Intake | 1 | 2020 | 171 | 0.160 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 9 | 0.160 |
Why?
| Eating | 1 | 2020 | 158 | 0.160 |
Why?
| Patient Care Team | 3 | 2013 | 258 | 0.160 |
Why?
| Case-Control Studies | 4 | 2019 | 1148 | 0.160 |
Why?
| Diastole | 2 | 2016 | 70 | 0.160 |
Why?
| Athletic Injuries | 1 | 2021 | 188 | 0.160 |
Why?
| Middle Cerebral Artery | 2 | 2016 | 34 | 0.160 |
Why?
| Diabetes, Gestational | 1 | 2019 | 53 | 0.160 |
Why?
| Freezing Reaction, Cataleptic | 1 | 2018 | 5 | 0.160 |
Why?
| Virus Replication | 1 | 2020 | 138 | 0.160 |
Why?
| Feedback | 1 | 2019 | 52 | 0.160 |
Why?
| Sheep | 1 | 2018 | 91 | 0.160 |
Why?
| Point Mutation | 1 | 2018 | 65 | 0.160 |
Why?
| Colorectal Surgery | 1 | 2018 | 17 | 0.160 |
Why?
| Cannabidiol | 1 | 2019 | 35 | 0.150 |
Why?
| Pyridones | 2 | 2009 | 35 | 0.150 |
Why?
| Receptors, Growth Factor | 2 | 2008 | 7 | 0.150 |
Why?
| Arkansas | 6 | 2019 | 1991 | 0.150 |
Why?
| Cell Line, Tumor | 7 | 2017 | 1399 | 0.150 |
Why?
| Treatment Outcome | 7 | 2017 | 5230 | 0.150 |
Why?
| Child | 8 | 2024 | 6877 | 0.150 |
Why?
| Burnout, Professional | 1 | 2019 | 51 | 0.150 |
Why?
| Body Mass Index | 4 | 2024 | 669 | 0.150 |
Why?
| Mental Health Services | 1 | 2021 | 202 | 0.150 |
Why?
| Certification | 1 | 2018 | 49 | 0.150 |
Why?
| Bone Development | 1 | 2018 | 64 | 0.150 |
Why?
| Military Personnel | 2 | 2019 | 165 | 0.150 |
Why?
| Blood Flow Velocity | 3 | 2016 | 100 | 0.150 |
Why?
| Foot | 1 | 2018 | 40 | 0.150 |
Why?
| Ethanol | 2 | 2011 | 336 | 0.150 |
Why?
| Walking | 1 | 2018 | 97 | 0.150 |
Why?
| United States | 7 | 2021 | 4913 | 0.150 |
Why?
| Cognition | 1 | 2020 | 314 | 0.150 |
Why?
| Action Potentials | 3 | 2012 | 134 | 0.140 |
Why?
| Psychiatry | 2 | 2017 | 105 | 0.140 |
Why?
| Proto-Oncogene Proteins | 2 | 2008 | 156 | 0.140 |
Why?
| Parathyroid Hormone-Related Protein | 1 | 2017 | 22 | 0.140 |
Why?
| Risk Factors | 6 | 2019 | 3692 | 0.140 |
Why?
| Cellular Microenvironment | 1 | 2017 | 27 | 0.140 |
Why?
| Platelet Activation | 1 | 2017 | 47 | 0.140 |
Why?
| Electroacupuncture | 1 | 2016 | 2 | 0.140 |
Why?
| Pilot Projects | 3 | 2017 | 704 | 0.140 |
Why?
| Substance-Related Disorders | 2 | 2014 | 595 | 0.140 |
Why?
| Epinephrine | 1 | 2017 | 96 | 0.140 |
Why?
| Blood Specimen Collection | 1 | 2016 | 36 | 0.130 |
Why?
| Combat Disorders | 1 | 2016 | 37 | 0.130 |
Why?
| Attention | 1 | 2017 | 166 | 0.130 |
Why?
| Perception | 1 | 2017 | 116 | 0.130 |
Why?
| Citrus paradisi | 2 | 2008 | 10 | 0.130 |
Why?
| Food-Drug Interactions | 2 | 2008 | 14 | 0.130 |
Why?
| Pain | 2 | 2016 | 374 | 0.130 |
Why?
| Temporal Lobe | 2 | 2017 | 70 | 0.130 |
Why?
| Neonatal Screening | 1 | 2016 | 47 | 0.130 |
Why?
| Quinolines | 2 | 2007 | 41 | 0.130 |
Why?
| Cell Membrane | 1 | 2017 | 249 | 0.130 |
Why?
| Itraconazole | 2 | 2008 | 41 | 0.130 |
Why?
| Career Choice | 1 | 2017 | 111 | 0.130 |
Why?
| Serotonin | 1 | 2017 | 152 | 0.130 |
Why?
| Cerebral Ventricles | 1 | 2016 | 28 | 0.130 |
Why?
| Antibodies, Viral | 2 | 2013 | 92 | 0.130 |
Why?
| Melatonin | 1 | 2015 | 16 | 0.130 |
Why?
| Quality of Life | 2 | 2019 | 844 | 0.130 |
Why?
| Arterial Pressure | 1 | 2016 | 45 | 0.130 |
Why?
| Physicians | 1 | 2019 | 229 | 0.130 |
Why?
| Muscle, Skeletal | 1 | 2021 | 781 | 0.120 |
Why?
| Bone Neoplasms | 1 | 2017 | 179 | 0.120 |
Why?
| Cholinergic Agonists | 2 | 2011 | 10 | 0.120 |
Why?
| Quality-Adjusted Life Years | 2 | 2015 | 63 | 0.120 |
Why?
| Xenograft Model Antitumor Assays | 3 | 2010 | 213 | 0.120 |
Why?
| Blood Platelets | 1 | 2017 | 252 | 0.120 |
Why?
| Signal Transduction | 2 | 2022 | 1625 | 0.120 |
Why?
| Excitatory Amino Acid Agonists | 2 | 2011 | 20 | 0.120 |
Why?
| Amphetamine | 1 | 2014 | 38 | 0.110 |
Why?
| Cell Differentiation | 1 | 2017 | 651 | 0.110 |
Why?
| Cyclohexanecarboxylic Acids | 1 | 2014 | 18 | 0.110 |
Why?
| Massage | 1 | 2014 | 6 | 0.110 |
Why?
| Severity of Illness Index | 4 | 2022 | 963 | 0.110 |
Why?
| Autistic Disorder | 1 | 2015 | 124 | 0.110 |
Why?
| Drinking | 2 | 2020 | 38 | 0.110 |
Why?
| Osteoclasts | 1 | 2017 | 424 | 0.110 |
Why?
| Behavior Therapy | 1 | 2015 | 180 | 0.110 |
Why?
| gamma-Aminobutyric Acid | 1 | 2014 | 63 | 0.110 |
Why?
| Equipment Failure Analysis | 1 | 2013 | 46 | 0.110 |
Why?
| Simian foamy virus | 1 | 2013 | 1 | 0.110 |
Why?
| Simian Acquired Immunodeficiency Syndrome | 1 | 2013 | 3 | 0.110 |
Why?
| Aged | 6 | 2021 | 9590 | 0.110 |
Why?
| Smoking | 1 | 2017 | 508 | 0.110 |
Why?
| Antifungal Agents | 2 | 2008 | 342 | 0.110 |
Why?
| Double-Blind Method | 4 | 2017 | 682 | 0.110 |
Why?
| Binding Sites | 2 | 2014 | 378 | 0.110 |
Why?
| Bacillus | 1 | 2012 | 5 | 0.110 |
Why?
| Biophysical Phenomena | 1 | 2012 | 19 | 0.110 |
Why?
| Nebulizers and Vaporizers | 1 | 2013 | 55 | 0.110 |
Why?
| Drug Contamination | 1 | 2012 | 5 | 0.110 |
Why?
| Kangaroo-Mother Care Method | 1 | 2013 | 7 | 0.100 |
Why?
| Child, Preschool | 4 | 2024 | 3908 | 0.100 |
Why?
| Albuterol | 1 | 2013 | 56 | 0.100 |
Why?
| Models, Biological | 3 | 2019 | 723 | 0.100 |
Why?
| Saliva | 1 | 2013 | 55 | 0.100 |
Why?
| Cardiotonic Agents | 1 | 2013 | 82 | 0.100 |
Why?
| Bronchodilator Agents | 1 | 2013 | 75 | 0.100 |
Why?
| Drug Overdose | 1 | 2014 | 160 | 0.100 |
Why?
| Primary Health Care | 3 | 2013 | 364 | 0.100 |
Why?
| Hydrocortisone | 1 | 2013 | 107 | 0.100 |
Why?
| Coculture Techniques | 1 | 2012 | 143 | 0.100 |
Why?
| Registries | 1 | 2015 | 539 | 0.100 |
Why?
| Hypotension | 1 | 2013 | 62 | 0.100 |
Why?
| Dopamine | 1 | 2013 | 171 | 0.100 |
Why?
| DNA, Viral | 1 | 2012 | 133 | 0.100 |
Why?
| Anthropometry | 2 | 2024 | 93 | 0.100 |
Why?
| Calcium Channels, N-Type | 1 | 2011 | 2 | 0.100 |
Why?
| Intralaminar Thalamic Nuclei | 1 | 2011 | 6 | 0.100 |
Why?
| Sequence Analysis, DNA | 1 | 2012 | 237 | 0.100 |
Why?
| Functional Laterality | 1 | 2012 | 86 | 0.100 |
Why?
| Fetal Death | 1 | 2011 | 23 | 0.100 |
Why?
| Dose-Response Relationship, Drug | 4 | 2019 | 1356 | 0.100 |
Why?
| Polymerase Chain Reaction | 1 | 2012 | 456 | 0.090 |
Why?
| Stem Cell Transplantation | 1 | 2012 | 179 | 0.090 |
Why?
| Blotting, Western | 1 | 2012 | 587 | 0.090 |
Why?
| Patch-Clamp Techniques | 4 | 2012 | 123 | 0.090 |
Why?
| Cells, Cultured | 2 | 2012 | 1589 | 0.090 |
Why?
| Pain Management | 1 | 2013 | 172 | 0.090 |
Why?
| Sleep, REM | 1 | 2011 | 44 | 0.090 |
Why?
| Pons | 1 | 2011 | 33 | 0.090 |
Why?
| Brain Waves | 1 | 2011 | 18 | 0.090 |
Why?
| Echoencephalography | 1 | 2011 | 9 | 0.090 |
Why?
| Nerve Fibers | 1 | 2011 | 12 | 0.090 |
Why?
| Neurogenesis | 1 | 2011 | 24 | 0.090 |
Why?
| Electrocardiography | 1 | 2012 | 267 | 0.090 |
Why?
| Stress, Psychological | 1 | 2013 | 261 | 0.090 |
Why?
| Longitudinal Studies | 3 | 2021 | 709 | 0.090 |
Why?
| Central Nervous System Depressants | 1 | 2011 | 79 | 0.090 |
Why?
| Carbon Dioxide | 1 | 2011 | 94 | 0.090 |
Why?
| Farnesyltranstransferase | 2 | 2007 | 5 | 0.090 |
Why?
| Social Environment | 1 | 2011 | 79 | 0.090 |
Why?
| Professional Role | 1 | 2011 | 76 | 0.090 |
Why?
| Atrial Fibrillation | 1 | 2012 | 189 | 0.090 |
Why?
| Administration, Oral | 4 | 2018 | 432 | 0.090 |
Why?
| Cerebellum | 1 | 2011 | 132 | 0.080 |
Why?
| Synapses | 1 | 2010 | 85 | 0.080 |
Why?
| Linear Models | 3 | 2016 | 279 | 0.080 |
Why?
| Parents | 1 | 2013 | 320 | 0.080 |
Why?
| Teaching | 1 | 2011 | 113 | 0.080 |
Why?
| Data Collection | 1 | 2011 | 283 | 0.080 |
Why?
| Chronic Disease | 1 | 2012 | 570 | 0.080 |
Why?
| Cross-Sectional Studies | 3 | 2021 | 1590 | 0.080 |
Why?
| Health Care Costs | 1 | 2010 | 168 | 0.080 |
Why?
| Dihydropyridines | 1 | 2009 | 8 | 0.080 |
Why?
| Drug Design | 1 | 2010 | 119 | 0.080 |
Why?
| Learning | 1 | 2011 | 158 | 0.080 |
Why?
| Gestational Age | 3 | 2019 | 426 | 0.080 |
Why?
| Young Adult | 5 | 2017 | 4064 | 0.080 |
Why?
| Diet, High-Fat | 2 | 2021 | 214 | 0.080 |
Why?
| Phosphotransferases | 1 | 2008 | 16 | 0.080 |
Why?
| Cooperative Behavior | 1 | 2010 | 226 | 0.080 |
Why?
| Body Weight | 2 | 2021 | 514 | 0.080 |
Why?
| Liver | 3 | 2019 | 1123 | 0.080 |
Why?
| Magnetic Resonance Imaging | 3 | 2021 | 1534 | 0.080 |
Why?
| Electroencephalography | 1 | 2010 | 304 | 0.080 |
Why?
| Mice, Inbred Strains | 2 | 2019 | 160 | 0.080 |
Why?
| Urea | 1 | 2008 | 80 | 0.070 |
Why?
| Beverages | 2 | 2008 | 56 | 0.070 |
Why?
| Triazines | 1 | 2008 | 24 | 0.070 |
Why?
| Logistic Models | 2 | 2012 | 900 | 0.070 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2008 | 51 | 0.070 |
Why?
| Breast Neoplasms | 1 | 2017 | 1189 | 0.070 |
Why?
| Adolescent | 5 | 2021 | 6475 | 0.070 |
Why?
| Stomach Neoplasms | 2 | 2008 | 189 | 0.070 |
Why?
| Plasmodium falciparum | 1 | 2007 | 19 | 0.070 |
Why?
| Antimalarials | 1 | 2007 | 24 | 0.070 |
Why?
| Swimming | 1 | 2006 | 22 | 0.070 |
Why?
| Glioma | 1 | 2007 | 76 | 0.070 |
Why?
| Bicycling | 1 | 2006 | 26 | 0.070 |
Why?
| Running | 1 | 2006 | 16 | 0.070 |
Why?
| Central Nervous System Stimulants | 1 | 2009 | 205 | 0.070 |
Why?
| Monitoring, Physiologic | 2 | 2019 | 121 | 0.070 |
Why?
| Chromatography, High Pressure Liquid | 2 | 2018 | 326 | 0.070 |
Why?
| Motor Activity | 3 | 2014 | 222 | 0.070 |
Why?
| Proportional Hazards Models | 1 | 2007 | 418 | 0.070 |
Why?
| Sulfonamides | 1 | 2007 | 125 | 0.070 |
Why?
| Fetus | 3 | 2014 | 218 | 0.060 |
Why?
| Receptors, Vasopressin | 1 | 2005 | 23 | 0.060 |
Why?
| Prospective Studies | 3 | 2019 | 2414 | 0.060 |
Why?
| Multiple Myeloma | 2 | 2012 | 2949 | 0.060 |
Why?
| Cell Survival | 3 | 2017 | 590 | 0.060 |
Why?
| Dogs | 2 | 2020 | 185 | 0.060 |
Why?
| Ambulatory Care | 2 | 2021 | 228 | 0.060 |
Why?
| Alkyl and Aryl Transferases | 1 | 2005 | 5 | 0.060 |
Why?
| Poliomyelitis | 1 | 2005 | 5 | 0.060 |
Why?
| Mice, Inbred C57BL | 2 | 2021 | 1785 | 0.060 |
Why?
| Benzodiazepines | 1 | 2005 | 70 | 0.060 |
Why?
| Spheroids, Cellular | 1 | 2005 | 24 | 0.060 |
Why?
| Ambulatory Care Facilities | 2 | 2021 | 121 | 0.060 |
Why?
| Area Under Curve | 3 | 2014 | 179 | 0.060 |
Why?
| Kinetics | 2 | 2020 | 635 | 0.060 |
Why?
| Cyclin-Dependent Kinases | 1 | 2004 | 26 | 0.060 |
Why?
| beta-Cyclodextrins | 1 | 2004 | 16 | 0.060 |
Why?
| Thiazoles | 1 | 2004 | 53 | 0.060 |
Why?
| Predictive Value of Tests | 2 | 2017 | 934 | 0.060 |
Why?
| Brain Neoplasms | 1 | 2007 | 288 | 0.060 |
Why?
| Protein Binding | 3 | 2014 | 657 | 0.060 |
Why?
| Placebos | 2 | 2014 | 84 | 0.050 |
Why?
| Louisiana | 2 | 2019 | 39 | 0.050 |
Why?
| Insurance, Psychiatric | 1 | 2003 | 3 | 0.050 |
Why?
| Insurance Benefits | 1 | 2003 | 7 | 0.050 |
Why?
| Cell Proliferation | 4 | 2008 | 989 | 0.050 |
Why?
| Odds Ratio | 2 | 2016 | 551 | 0.050 |
Why?
| Health Services | 1 | 2003 | 65 | 0.050 |
Why?
| Community Mental Health Services | 1 | 2003 | 45 | 0.050 |
Why?
| Palmitates | 1 | 2022 | 29 | 0.050 |
Why?
| Drug Evaluation, Preclinical | 2 | 2017 | 145 | 0.050 |
Why?
| L-Lactate Dehydrogenase | 1 | 2022 | 70 | 0.050 |
Why?
| Models, Molecular | 3 | 2009 | 334 | 0.050 |
Why?
| Sex Factors | 2 | 2019 | 702 | 0.050 |
Why?
| Clinical Competence | 2 | 2018 | 397 | 0.050 |
Why?
| Reproducibility of Results | 2 | 2019 | 1201 | 0.050 |
Why?
| Statistics, Nonparametric | 2 | 2012 | 193 | 0.050 |
Why?
| Physical Therapy Modalities | 1 | 2021 | 36 | 0.050 |
Why?
| Medically Uninsured | 1 | 2021 | 45 | 0.050 |
Why?
| Glucose Tolerance Test | 1 | 2021 | 57 | 0.050 |
Why?
| Carbachol | 2 | 2011 | 27 | 0.050 |
Why?
| Psychiatric Status Rating Scales | 2 | 2013 | 322 | 0.050 |
Why?
| Postural Balance | 1 | 2021 | 58 | 0.050 |
Why?
| Athletes | 1 | 2021 | 98 | 0.050 |
Why?
| Sodium Channel Blockers | 2 | 2011 | 13 | 0.050 |
Why?
| Membrane Potentials | 2 | 2011 | 117 | 0.050 |
Why?
| Weight Gain | 1 | 2022 | 236 | 0.050 |
Why?
| Analysis of Variance | 2 | 2013 | 562 | 0.040 |
Why?
| Diet, Fat-Restricted | 1 | 2020 | 12 | 0.040 |
Why?
| Veterans Health | 1 | 2021 | 62 | 0.040 |
Why?
| Attitude | 1 | 2021 | 69 | 0.040 |
Why?
| Mice, Obese | 1 | 2020 | 20 | 0.040 |
Why?
| Fatty Acids | 1 | 2021 | 145 | 0.040 |
Why?
| Body Fat Distribution | 1 | 2020 | 9 | 0.040 |
Why?
| Animals, Newborn | 2 | 2012 | 367 | 0.040 |
Why?
| Cytopathogenic Effect, Viral | 1 | 2020 | 5 | 0.040 |
Why?
| Macaca | 1 | 2020 | 7 | 0.040 |
Why?
| Reaction Time | 1 | 2021 | 215 | 0.040 |
Why?
| Adipose Tissue, Brown | 1 | 2020 | 40 | 0.040 |
Why?
| Lipid Metabolism | 1 | 2021 | 176 | 0.040 |
Why?
| Oxidation-Reduction | 1 | 2021 | 317 | 0.040 |
Why?
| Absorptiometry, Photon | 1 | 2020 | 155 | 0.040 |
Why?
| Alcoholism | 1 | 2003 | 232 | 0.040 |
Why?
| Neuroimaging | 1 | 2020 | 86 | 0.040 |
Why?
| Memory | 1 | 2020 | 107 | 0.040 |
Why?
| Exercise | 1 | 2024 | 505 | 0.040 |
Why?
| Patient Compliance | 2 | 2014 | 231 | 0.040 |
Why?
| Sex Characteristics | 1 | 2021 | 198 | 0.040 |
Why?
| Proteomics | 1 | 2022 | 299 | 0.040 |
Why?
| Cohort Studies | 2 | 2016 | 1426 | 0.040 |
Why?
| Family Relations | 1 | 2019 | 22 | 0.040 |
Why?
| Language | 1 | 2020 | 137 | 0.040 |
Why?
| Phylogeny | 1 | 2020 | 234 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 152 | 0.040 |
Why?
| Students | 1 | 2021 | 222 | 0.040 |
Why?
| Mothers | 1 | 2021 | 256 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 168 | 0.040 |
Why?
| Neuropsychological Tests | 1 | 2020 | 337 | 0.040 |
Why?
| Specialty Boards | 1 | 2018 | 24 | 0.040 |
Why?
| Interpersonal Relations | 1 | 2019 | 104 | 0.040 |
Why?
| Retrospective Studies | 2 | 2012 | 6223 | 0.040 |
Why?
| Mice, Knockout | 1 | 2021 | 840 | 0.040 |
Why?
| Caco-2 Cells | 2 | 2008 | 26 | 0.040 |
Why?
| Animals, Outbred Strains | 1 | 2017 | 11 | 0.040 |
Why?
| Social Support | 1 | 2019 | 263 | 0.040 |
Why?
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2017 | 9 | 0.040 |
Why?
| Transglutaminases | 1 | 2017 | 15 | 0.040 |
Why?
| Parietal Lobe | 1 | 2017 | 25 | 0.040 |
Why?
| Cell Line | 1 | 2020 | 1010 | 0.040 |
Why?
| Plant Extracts | 1 | 2019 | 166 | 0.040 |
Why?
| Toxicity Tests | 1 | 2017 | 54 | 0.040 |
Why?
| Mice, Inbred BALB C | 2 | 2008 | 297 | 0.040 |
Why?
| Adaptation, Psychological | 1 | 2019 | 226 | 0.040 |
Why?
| Emergency Service, Hospital | 1 | 2021 | 482 | 0.040 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 63 | 0.040 |
Why?
| Platelet Aggregation | 1 | 2017 | 71 | 0.030 |
Why?
| Organ Size | 1 | 2017 | 223 | 0.030 |
Why?
| Polysaccharides | 1 | 2017 | 51 | 0.030 |
Why?
| Feeding Behavior | 1 | 2018 | 177 | 0.030 |
Why?
| Prognosis | 1 | 2022 | 1979 | 0.030 |
Why?
| Educational Measurement | 1 | 2018 | 205 | 0.030 |
Why?
| Medicine | 1 | 2017 | 56 | 0.030 |
Why?
| Education, Medical, Graduate | 1 | 2019 | 213 | 0.030 |
Why?
| Prefrontal Cortex | 1 | 2017 | 83 | 0.030 |
Why?
| Cannabis | 1 | 2019 | 141 | 0.030 |
Why?
| Mice, Nude | 2 | 2009 | 252 | 0.030 |
Why?
| Psychomotor Performance | 1 | 2017 | 123 | 0.030 |
Why?
| Accidental Falls | 1 | 2018 | 104 | 0.030 |
Why?
| Protein Transport | 1 | 2017 | 183 | 0.030 |
Why?
| Adrenergic beta-Antagonists | 1 | 2017 | 108 | 0.030 |
Why?
| Inhibitory Concentration 50 | 2 | 2008 | 71 | 0.030 |
Why?
| Umbilical Arteries | 1 | 2016 | 22 | 0.030 |
Why?
| Pharmaceutical Solutions | 2 | 2008 | 8 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2017 | 235 | 0.030 |
Why?
| Ultrasonography, Doppler, Transcranial | 1 | 2016 | 21 | 0.030 |
Why?
| Autonomic Nervous System | 1 | 2016 | 59 | 0.030 |
Why?
| Apgar Score | 1 | 2016 | 34 | 0.030 |
Why?
| Molecular Structure | 2 | 2008 | 293 | 0.030 |
Why?
| Tandem Mass Spectrometry | 1 | 2017 | 237 | 0.030 |
Why?
| Prevalence | 1 | 2019 | 970 | 0.030 |
Why?
| Infant, Extremely Premature | 1 | 2016 | 35 | 0.030 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2017 | 174 | 0.030 |
Why?
| Up-Regulation | 1 | 2017 | 449 | 0.030 |
Why?
| Echocardiography | 1 | 2018 | 398 | 0.030 |
Why?
| Calcium | 1 | 2017 | 401 | 0.030 |
Why?
| Cost of Illness | 1 | 2015 | 113 | 0.030 |
Why?
| Binding Sites, Antibody | 1 | 2014 | 16 | 0.030 |
Why?
| GABA Agonists | 1 | 2014 | 14 | 0.030 |
Why?
| Diagnosis, Dual (Psychiatry) | 1 | 2014 | 41 | 0.030 |
Why?
| Half-Life | 1 | 2014 | 85 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2016 | 583 | 0.030 |
Why?
| Locomotion | 1 | 2014 | 84 | 0.030 |
Why?
| Gene Expression Profiling | 1 | 2018 | 1029 | 0.030 |
Why?
| MicroRNAs | 1 | 2017 | 350 | 0.030 |
Why?
| Amphetamine-Related Disorders | 1 | 2014 | 93 | 0.030 |
Why?
| CD4 Lymphocyte Count | 1 | 2013 | 32 | 0.030 |
Why?
| Particle Size | 1 | 2013 | 80 | 0.030 |
Why?
| Administration, Inhalation | 1 | 2013 | 111 | 0.030 |
Why?
| T-Lymphocyte Subsets | 1 | 2013 | 38 | 0.030 |
Why?
| Aerosols | 1 | 2013 | 74 | 0.030 |
Why?
| Plasma | 1 | 2013 | 42 | 0.030 |
Why?
| Infant, Extremely Low Birth Weight | 1 | 2013 | 27 | 0.030 |
Why?
| Biophysics | 1 | 2012 | 16 | 0.030 |
Why?
| Nasal Cavity | 1 | 2013 | 7 | 0.030 |
Why?
| Viral Load | 1 | 2013 | 76 | 0.030 |
Why?
| Touch | 1 | 2013 | 25 | 0.030 |
Why?
| Theophylline | 1 | 2012 | 21 | 0.030 |
Why?
| Ion Channel Gating | 1 | 2012 | 40 | 0.030 |
Why?
| Infant Behavior | 1 | 2013 | 18 | 0.030 |
Why?
| Medically Underserved Area | 1 | 2013 | 42 | 0.030 |
Why?
| Neurotransmitter Agents | 1 | 2012 | 35 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2014 | 383 | 0.030 |
Why?
| Electric Stimulation | 1 | 2012 | 117 | 0.030 |
Why?
| Remission Induction | 1 | 2013 | 206 | 0.030 |
Why?
| Medication Adherence | 1 | 2014 | 129 | 0.030 |
Why?
| Equipment Design | 1 | 2013 | 290 | 0.030 |
Why?
| Intensive Care Units, Neonatal | 1 | 2014 | 123 | 0.030 |
Why?
| Sleep | 1 | 2014 | 180 | 0.030 |
Why?
| Systole | 1 | 2012 | 72 | 0.030 |
Why?
| Caffeine | 1 | 2012 | 64 | 0.030 |
Why?
| Ion Channels | 1 | 2012 | 74 | 0.030 |
Why?
| Heart Atria | 1 | 2012 | 61 | 0.020 |
Why?
| Psychotherapy | 1 | 2013 | 106 | 0.020 |
Why?
| Recurrence | 1 | 2014 | 664 | 0.020 |
Why?
| omega-Agatoxin IVA | 1 | 2011 | 1 | 0.020 |
Why?
| Infant | 1 | 2020 | 3601 | 0.020 |
Why?
| Combined Modality Therapy | 1 | 2014 | 641 | 0.020 |
Why?
| Antidepressive Agents | 1 | 2013 | 176 | 0.020 |
Why?
| Oscillometry | 1 | 2011 | 9 | 0.020 |
Why?
| Survival Analysis | 1 | 2013 | 671 | 0.020 |
Why?
| Ventricular Dysfunction, Left | 1 | 2012 | 104 | 0.020 |
Why?
| Sodium Channels | 1 | 2011 | 14 | 0.020 |
Why?
| Calcium Channel Blockers | 1 | 2011 | 64 | 0.020 |
Why?
| Secondary Prevention | 1 | 2011 | 79 | 0.020 |
Why?
| Cystic Fibrosis | 1 | 2013 | 151 | 0.020 |
Why?
| Acculturation | 1 | 2011 | 21 | 0.020 |
Why?
| Principal Component Analysis | 1 | 2011 | 54 | 0.020 |
Why?
| Social Identification | 1 | 2011 | 21 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2011 | 112 | 0.020 |
Why?
| Microscopy, Confocal | 1 | 2011 | 83 | 0.020 |
Why?
| Femoral Artery | 1 | 2011 | 105 | 0.020 |
Why?
| Clinical Clerkship | 1 | 2011 | 29 | 0.020 |
Why?
| Statistics as Topic | 1 | 2011 | 87 | 0.020 |
Why?
| Transplantation, Autologous | 1 | 2012 | 464 | 0.020 |
Why?
| Ultrasonography | 1 | 2012 | 438 | 0.020 |
Why?
| Vesicular Glutamate Transport Protein 2 | 1 | 2010 | 6 | 0.020 |
Why?
| Cerebellar Cortex | 1 | 2010 | 6 | 0.020 |
Why?
| Tetrodotoxin | 1 | 2010 | 10 | 0.020 |
Why?
| Electrophysiological Phenomena | 1 | 2010 | 18 | 0.020 |
Why?
| N-Methylaspartate | 1 | 2010 | 27 | 0.020 |
Why?
| Theta Rhythm | 1 | 2010 | 10 | 0.020 |
Why?
| Muscarinic Agonists | 1 | 2010 | 11 | 0.020 |
Why?
| Potassium Channel Blockers | 1 | 2010 | 17 | 0.020 |
Why?
| Schools, Medical | 1 | 2011 | 70 | 0.020 |
Why?
| Kainic Acid | 1 | 2010 | 29 | 0.020 |
Why?
| Disease Progression | 1 | 2013 | 823 | 0.020 |
Why?
| Potassium Channels | 1 | 2010 | 33 | 0.020 |
Why?
| Kidney Diseases | 1 | 2012 | 213 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2011 | 466 | 0.020 |
Why?
| Cell Count | 1 | 2010 | 147 | 0.020 |
Why?
| Pregnancy Outcome | 1 | 2011 | 237 | 0.020 |
Why?
| Stereotyped Behavior | 1 | 2009 | 17 | 0.020 |
Why?
| Image Processing, Computer-Assisted | 1 | 2011 | 242 | 0.020 |
Why?
| Age Factors | 1 | 2013 | 1104 | 0.020 |
Why?
| Dextroamphetamine | 1 | 2009 | 39 | 0.020 |
Why?
| Incidence | 1 | 2012 | 1017 | 0.020 |
Why?
| Blood Proteins | 1 | 2009 | 77 | 0.020 |
Why?
| Fetal Development | 1 | 2009 | 59 | 0.020 |
Why?
| Solubility | 1 | 2009 | 72 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2009 | 213 | 0.020 |
Why?
| fms-Like Tyrosine Kinase 3 | 1 | 2008 | 16 | 0.020 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 30 | 0.020 |
Why?
| Ether-A-Go-Go Potassium Channels | 1 | 2008 | 5 | 0.020 |
Why?
| Risk Assessment | 1 | 2012 | 1258 | 0.020 |
Why?
| Kidney | 1 | 2012 | 686 | 0.020 |
Why?
| Parasitic Sensitivity Tests | 1 | 2007 | 2 | 0.020 |
Why?
| Dealkylation | 1 | 2007 | 4 | 0.020 |
Why?
| Plasmodium berghei | 1 | 2007 | 4 | 0.020 |
Why?
| Cell Membrane Permeability | 1 | 2007 | 28 | 0.020 |
Why?
| Protein Conformation | 1 | 2008 | 165 | 0.020 |
Why?
| Mutagenicity Tests | 1 | 2007 | 42 | 0.020 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2008 | 77 | 0.020 |
Why?
| Hypertension | 1 | 2012 | 550 | 0.020 |
Why?
| Glutathione Transferase | 1 | 2008 | 174 | 0.020 |
Why?
| Bile Ducts | 1 | 2007 | 49 | 0.020 |
Why?
| Malaria | 1 | 2007 | 37 | 0.020 |
Why?
| Physical Endurance | 1 | 2006 | 30 | 0.020 |
Why?
| Exercise Tolerance | 1 | 2006 | 40 | 0.020 |
Why?
| Hepatocytes | 1 | 2008 | 179 | 0.020 |
Why?
| Computer Simulation | 1 | 2007 | 284 | 0.020 |
Why?
| Respiration | 1 | 2006 | 100 | 0.020 |
Why?
| Benzazepines | 1 | 2005 | 20 | 0.020 |
Why?
| Molecular Weight | 1 | 2005 | 85 | 0.020 |
Why?
| Oxygen Consumption | 1 | 2006 | 189 | 0.020 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2006 | 244 | 0.020 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2005 | 131 | 0.010 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2007 | 556 | 0.010 |
Why?
| Cyclodextrins | 1 | 2004 | 18 | 0.010 |
Why?
| Tumor Cells, Cultured | 1 | 2005 | 462 | 0.010 |
Why?
| Biological Availability | 1 | 2004 | 100 | 0.010 |
Why?
| Leukemia | 1 | 2004 | 64 | 0.010 |
Why?
| Neoplasms, Experimental | 1 | 2004 | 111 | 0.010 |
Why?
| Gatekeeping | 1 | 2003 | 9 | 0.010 |
Why?
| Cost Control | 1 | 2003 | 13 | 0.010 |
Why?
| Tennessee | 1 | 2003 | 36 | 0.010 |
Why?
| Cost Sharing | 1 | 2003 | 16 | 0.010 |
Why?
| Georgia | 1 | 2003 | 42 | 0.010 |
Why?
| Alabama | 1 | 2003 | 66 | 0.010 |
Why?
| Mississippi | 1 | 2003 | 88 | 0.010 |
Why?
| Health Policy | 1 | 2003 | 152 | 0.010 |
Why?
|
|
Williams's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|